MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia

Key Points

• The study aims to explore the role of MEF2A in promoting drug resistance and cancer progression in acute myeloid leukemia.
• Investigated the relationship between MEF2A and ZDHHC20 expression levels.
• Analyzed the activation of the NF-κB pathway in response to MEF2A.
• Evaluated the impact of targeting the MEF2A/ZDHHC20 axis on drug resistance.
• MEF2A enhances ZDHHC20 expression, leading to NF-κB pathway activation.
• Doxorubicin sensitivity is reduced in models where MEF2A is active.
• Targeting MEF2A/ZDHHC20 shows promise for overcoming drug resistance.